MacroGenics regains global rights to DART molecule for autoimmune disorders
MacroGenics and Takeda Pharmaceutical Company announced the conclusion of their license and option agreement for MGD010.
MacroGenics has regained the worldwide rights to MGD010, a bispecific molecule targeting CD32B and CD79B. Takeda’s decision comes earlier than the predefined expiration of its option exercise period and follows Takeda’s recently announced therapeutic area re-prioritization.
Click on this link for more information.
